. Cost-effectiveness of strategies by foci (Sutherland et al, 2017) 2 Table 2 . Cost-effectiveness of strategies by foci (Sutherland et 
A.1 Defining national programs using a "rationale choice" approach
The programs for Control, Elimination I, Elimination II and Elimination III described in the main manuscripts were developed using a "rationale choice approach". During priority setting for new technologies within a given budget, decision makers may use a "rational choice" approach that includes choosing the most cost-effective interventions. In this case, it was assumed that the incremental cost-effectiveness ratios (ICERs) would guide which strategies per foci should be selected for a national elimination program based on cost-effective as per Sutherland et However, the sensitivity analysis (SA) demonstrated that increased surveillance could be costeffective (Refer to Table 2 ). When it was compared to the current interventions it was the dominant choice (cost less, more effects); both strategy E and B were dominated by it. Hence, strategy D plus bi-annual surveillance could be considered a cost-effective strategy for decision makers with a cost-effectiveness threshold near $650 per DALY averted or greater. Therefore it was decided that three options (strategies A, D or D+) could potentially be available in low transmission areas depending on cost-effectiveness thresholds (near or less than $1500 per DALY averted) and feasibility of running additional surveillance programs.
This cost-effectiveness threshold was considered, as the median of the gross national incomes (GNIs) from the impacted nations was near $1410. In cases where there was no ICER since the strategy was the comparator, the strategy with the lowest cost was considered. Refer to Table   3 . less than 500 cases could be feasible by 2020, and also contain strategies that have the highest probability of elimination [1] . 
A.3.2 Out-of-pocket (OOP) Household health expenditures related to T.b. gambiense
A cost function for per household OOP expenditure was then developed taking into consideration that a family member or friend would attend the treatment clinic with the diagnosed individual, and was calculated according to Equation 3 in the main manuscript.
The average cost of treatment for stage 1 and 2 is used as the final mean OOP costs per program (refer to Table 6 ). 
